Published in Gene on December 27, 2005
EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell (2012) 3.19
Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A (2007) 2.10
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04
The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci (2008) 2.00
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer (2010) 1.97
Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys (2008) 1.97
Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.85
Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood (2010) 1.81
Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev Cell (2013) 1.78
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol (2009) 1.78
Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett (2007) 1.62
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A (2006) 1.61
Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One (2011) 1.59
EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget (2010) 1.53
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer (2010) 1.52
PET tracers based on Zirconium-89. Curr Radiopharm (2011) 1.48
Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol (2008) 1.47
Cytohesins/ARNO: the function in colorectal cancer cells. PLoS One (2014) 1.45
Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor. PLoS One (2014) 1.41
Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res (2008) 1.37
ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.36
The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer (2011) 1.34
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One (2013) 1.32
Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett (2010) 1.30
Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS One (2008) 1.30
Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol (2010) 1.30
RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res (2008) 1.30
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells. J Biol Chem (2008) 1.27
MAGIA²: from miRNA and genes expression data integrative analysis to microRNA-transcription factor mixed regulatory circuits (2012 update). Nucleic Acids Res (2012) 1.27
Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proc Natl Acad Sci U S A (2013) 1.26
Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget (2010) 1.24
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res (2007) 1.22
Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res (2007) 1.21
Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol (2009) 1.19
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res (2008) 1.19
Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol (2008) 1.18
EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. Biochem J (2008) 1.18
High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One (2011) 1.17
Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry (2009) 1.16
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther (2007) 1.14
EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int J Med Sci (2013) 1.14
Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res (2008) 1.13
TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res (2008) 1.12
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. FEBS J (2013) 1.12
Protein glycosylation in cancer. Annu Rev Pathol (2015) 1.11
The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol (2013) 1.11
Positron emission tomography imaging of prostate cancer. Amino Acids (2009) 1.11
Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol (2013) 1.10
Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer (2009) 1.09
Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. J Transl Med (2013) 1.09
Cancer proteomics by quantitative shotgun proteomics. Mol Oncol (2007) 1.08
Flotillins in receptor tyrosine kinase signaling and cancer. Cells (2014) 1.08
MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Physiol Rep (2014) 1.07
Targeting EGFR resistance networks in head and neck cancer. Cell Signal (2009) 1.07
Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal (2008) 1.06
Role of G12 proteins in oncogenesis and metastasis. Br J Pharmacol (2009) 1.05
Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res (2010) 1.05
HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One (2011) 1.05
The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochim Biophys Acta (2007) 1.05
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther (2013) 1.03
Filamin A modulates kinase activation and intracellular trafficking of epidermal growth factor receptors in human melanoma cells. Endocrinology (2009) 1.03
The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. Carcinogenesis (2009) 1.02
EGF-induced centrosome separation promotes mitotic progression and cell survival. Dev Cell (2013) 1.01
Identification of disulfide-linked dimers of the receptor tyrosine kinase DDR1. J Biol Chem (2007) 1.00
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat (2009) 1.00
Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J (2008) 1.00
Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2. Proc Natl Acad Sci U S A (2010) 1.00
HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol (2009) 1.00
Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci U S A (2011) 0.99
Aberrant signaling pathways in squamous cell lung carcinoma. Cancer Inform (2011) 0.99
Epidermal growth factor signalling and bone metastasis. Br J Cancer (2009) 0.98
Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol (2013) 0.97
Receptor type protein tyrosine phosphatase-kappa mediates cross-talk between transforming growth factor-beta and epidermal growth factor receptor signaling pathways in human keratinocytes. Mol Biol Cell (2009) 0.97
The Drosophila cyst stem cell lineage: Partners behind the scenes? Spermatogenesis (2012) 0.96
Targeting the EGF receptor for ovarian cancer therapy. J Oncol (2009) 0.96
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer (2008) 0.96
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep (2009) 0.96
The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways. J Biol Chem (2010) 0.96
Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther (2012) 0.95
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers (Basel) (2014) 0.95
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer (2006) 0.95
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget (2013) 0.95
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs. Mol Cancer Res (2009) 0.94
A network-based gene-weighting approach for pathway analysis. Cell Res (2011) 0.94
Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res (2010) 0.94
Radionuclide carriers for targeting of cancer. Int J Nanomedicine (2008) 0.94
Macrophage migration inhibitory factor and interleukin-8 produced by gastric epithelial cells during Helicobacter pylori exposure induce expression and activation of the epidermal growth factor receptor. Infect Immun (2008) 0.93
An analysis of growth, differentiation and apoptosis genes with risk of renal cancer. PLoS One (2009) 0.93
Alteration of EGFR spatiotemporal dynamics suppresses signal transduction. PLoS One (2012) 0.93
GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol (2012) 0.93
Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF. PLoS One (2011) 0.93
Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene (2015) 0.92
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol (2016) 0.91
IQGAP3 promotes EGFR-ERK signaling and the growth and metastasis of lung cancer cells. PLoS One (2014) 0.91
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology (2011) 0.91
IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol (2007) 4.54
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature (2008) 4.28
Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity (2013) 2.78
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets (2012) 2.55
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol (2009) 2.48
The role of the EGFR signaling in tumor microenvironment. J Cell Physiol (2008) 2.34
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer (2005) 1.81
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol (2009) 1.71
Growth-associated protein 43-positive sensory nerve fibers accompanied by immature vessels are located in or near peritoneal endometriotic lesions. Fertil Steril (2007) 1.70
Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol (2004) 1.69
Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene (2005) 1.60
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol (2002) 1.53
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist (2009) 1.53
Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol (2002) 1.53
Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res (2010) 1.49
Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis. Am J Respir Crit Care Med (2013) 1.45
IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. J Immunol (2008) 1.40
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol (2006) 1.37
ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.36
A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res (2003) 1.32
Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. Am J Respir Crit Care Med (2013) 1.28
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest (2003) 1.27
Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol (2005) 1.26
Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol (2007) 1.26
Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics (2009) 1.22
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol (2003) 1.22
Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene (2005) 1.22
Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling. Oncogene (2005) 1.21
Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle (2008) 1.20
Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am J Pathol (2012) 1.20
Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res (2006) 1.18
A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS One (2012) 1.17
Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration. J Biol Chem (2007) 1.14
Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for trans activity as a Nodal co-receptor. J Biol Chem (2007) 1.14
Cripto: a tumor growth factor and more. J Cell Physiol (2002) 1.13
Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol (2004) 1.12
Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nat Commun (2012) 1.11
IL-17/Th17 in anti-fungal immunity: what's new? Eur J Immunol (2009) 1.11
Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst (2005) 1.10
Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol (2008) 1.10
TLR3 essentially promotes protective class I-restricted memory CD8⁺ T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients. Blood (2011) 1.09
Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol (2010) 1.09
Smad2 functions as a co-activator of canonical Wnt/beta-catenin signaling pathway independent of Smad4 through histone acetyltransferase activity of p300. Cell Signal (2008) 1.08
The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer (2007) 1.07
Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol (2009) 1.06
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat (2009) 1.06
Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis. Cell Mol Immunol (2012) 1.05
Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem (2013) 1.04
Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. Oncology (2015) 1.03
High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun (2013) 1.03
Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. J Cell Biol (2009) 1.03
Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis (2008) 1.03
EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther (2009) 1.00
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol (2003) 1.00
Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. FASEB J (2011) 1.00
Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am J Pathol (2005) 0.99
Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo. J Cell Sci (2005) 0.99
Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells (2010) 0.99
Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. J Cell Physiol (2008) 0.99